Tech Company Financing Transactions
Adela Funding Round
Adela, operating out of Los Angeles, secured $60 million in investment from F-Prime Capital, Decheng Capital and Deerfield Capital.
Transaction Overview
Company Name
Announced On
6/24/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The Series A funding will support advancing Adela's technology towards commercialization, with initial applications across the cancer care continuum from early detection to disease monitoring.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9595 Wilshire Blvd.
Los Angeles, CA 90212
USA
Los Angeles, CA 90212
USA
Phone
Undisclosed
Website
Email Address
Overview
Adela's mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela's genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network's Princess Margaret Cancer Centre.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Bratman
Chief Medical Officer
Anne-Renee Hartman
Chief Operating Officer
Todd Arnold
Chief Scientific Officer
Daniel De Carvalho
Controller
Priscilla Huang
VP - General Counsel
Karla Jarvis
Browse more venture capital transactions:
Prev: 6/24/2021: Rheaply venture capital transaction
Next: 6/24/2021: Moth+Flame venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs